EMA: 7 product-specific guidances adopted [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2015-07-07 16:10 (3656 d 05:40 ago) – Posting: # 15048
Views: 19,063

Dear all,

today the EMA published a new batch of product specific guidances (capecitabine, sirolimus, sorafenib, sunitinib, tadalafil, telithro­mycin, and vori­con­azole). The guidances were adopted by the CHMP on 21 May 2015 and will come into effect on 1 December 2015.
The “Compilation of individual product-specific guidance on demonstration of bio­equi­va­lence” Rev. 2 gives in its new Annex C as the effective date 1 November 2015. Lacking QA?

Links to all documents here.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,677 registered users;
50 visitors (0 registered, 50 guests [including 10 identified bots]).
Forum time: 21:51 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5